THOMAS JEFFERSON UNIVERSITY

IDEAYA Biosciences reports positive Phase 2 data for darovasertib in neoadjuvant uveal melanoma, with ~49% tumor shrinkage and ~61% eye preservation. A Phase 3 registrational trial is planned following FDA guidance, targeting ~400 patients with potential broad indication for low, intermediate, and high-risk metastatic disease.

IDEAYA Biosciences reports positive Phase 2 data for darovasertib in neoadjuvant uveal melanoma, showing ~49% tumor shrinkage and ~61% eye preservation rate. The company plans to initiate a Phase 3 registrational trial following FDA guidance, targeting ~400 patients with primary endpoints of eye preservation and time to vision loss.

Thomas Jefferson University offers over 200 programs in various fields, including medicine and health, with 8,300 students, 2,100 residents, and 1,900 faculty members. The university has developed over 1,000 patents, impacting patient care. Nearly 200 alumni serve as doctors and nurses at LVHN, embodying the university's values.

Kaida BioPharma launches social media channels to share updates on its innovative ovarian cancer treatment, KAD101, targeting Phase 1 study in 2025.

Bio-Path Holdings announces publication in 'Biomedicines' on BP1003's broad anti-tumor effect in solid tumors like breast, ovarian, and pancreatic cancer. BP1003 targets STAT3 mRNA, enhancing stability and cellular uptake, potentially improving chemotherapy efficacy in various cancers.

Medtronic's DBS system, approved for use during sleep, is the first to offer DBS surgery under both asleep and awake conditions, enhancing treatment flexibility. The Percept™ PC and RC neurostimulators allow DBS to remain ON during MRI scans, backed by extensive research. Medtronic's BrainSense™ technology provides real-time brain signal data, enabling personalized care. The Percept™ RC neurostimulator, launched in January 2024, offers a 15-year battery life and rapid recharging. Asleep DBS, approved in July 2024, addresses patient anxiety about awake surgery, ensuring comparable motor symptom improvement.

Locations include Yale New Haven Hospital - Yale Cancer Center in Connecticut, Karmanos Cancer Institute in Michigan, University of Minnesota Medical School in Minnesota, Washington University School of Medicine in Missouri, Oncology Hematology Care Clinial Trials in Ohio, OU Health Stephenson Cancer Center in Oklahoma, Thomas Jefferson University in Pennsylvania, Sarah Cannon Research Institute (SCRI) - Nashville in Tennessee, and The University of Texas MD Anderson Cancer Center in Texas.

A Drexel-led study, part of the Sidney Kimmel Comprehensive Cancer Center Research Consortium, showed significant improvements in participants' food choices after engaging with a coach. The study highlights the importance of behavioral science in helping adults make healthy choices, underscoring the need for interdisciplinary collaboration in cancer research and prevention. The consortium, recently awarded comprehensive status by the National Cancer Institute, leverages the expertise of multiple Drexel colleges and Thomas Jefferson University to develop transformative approaches in cancer prevention and treatment.